International Bladder Cancer Group

What International Bladder Cancer Group does

The International Bladder Cancer Group (IBCG) is a 501(c)(3) non-profit consortium founded in 2006 that convenes clinicians, researchers, regulators, and patient advocates to advance evidence-based care for bladder cancer. The organization operates through consensus-driven working groups, peer-reviewed publications, and an annual retreat in Houston, with the third edition (IBCG25) held August 21–23, 2025 drawing 100+ participants from 25+ countries across the Americas, Europe, and Asia. Its flagship intellectual output is the IBCG Risk Stratification Framework for intermediate-risk non-muscle-invasive bladder cancer (NMIBC), which was adopted into the NCCN 2026 Clinical Practice Guidelines in Oncology for Bladder Cancer following more than a decade of collaborative work.

IBCG's product surface is built around four primary offerings: the Risk Stratification Framework for clinical decision support, the Annual Retreat for expert collaboration and consensus-building, a newsletter publication archived from 2022 onward, and the membership program (now expanded with a 2025 Trainee category) that channels clinicians and fellows into working groups. Supporting mechanisms include the IBCG Champion Award, recognizing senior leaders such as 2025 recipient Dr. Joan Palou, and the Travel Award, providing up to $1,000 in travel support and complimentary retreat access for emerging researchers such as 2025 recipient Dr. Roberto Contieri. The organization is led by President Dr. Ashish Kamat and structured as an expert-governed consortium with no external parent, private equity, or venture ownership.

The business model is non-commercial: as a 501(c)(3), IBCG is funded through membership contributions, educational programs, and collaborative research initiatives rather than product sales or licensing. It monetizes influence rather than products, distributing its clinical frameworks and guidelines through direct member engagement, the NCCN integration channel, partner networks including UroToday, BCAN, WBCPC, and GSRGT, and digital channels such as its website, newsletters, X (Twitter), and YouTube. With no disclosed revenue, headcount, or pricing data, IBCG operates as a high-leverage, low-budget standards-setting body whose competitive position rests on its regulatory adoption and ecosystem participation rather than on commercial scale.

Name

International Bladder Cancer Group

Legal name

International Bladder Cancer Group

Website

https://ibcg.info

Company type

Private

Founded year

2006

Operating status

Operating

Short description

International Bladder Cancer Group is a 501(c)(3) non-profit consortium uniting 100+ global clinicians, researchers, regulators, and patient advocates across 25+ countries to develop evidence-based bladder cancer guidelines, risk stratification frameworks, and educational initiatives.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Non-profit organizational activities: As a 501(c)(3) non-profit organization, IBCG operates through membership contributions, educational programs, and collaborative research initiatives rather than commercial revenue generation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

IBCG is a global consortium of clinicians, researchers, regulators, and patient advocates that develops evidence-based bladder cancer treatment guidelines, risk stratification frameworks, and educational resources. Its deliverables include consensus statements, peer-reviewed clinical publications, the NMIBC risk stratification framework (adopted by NCCN 2026), annual retreats, and trainee-focused programs serving the international urological community.

Product overview

The International Bladder Cancer Group (IBCG) is a global consortium of experts (not a traditional technology company) committed to improving outcomes for patients with bladder cancer. The organization operates through critical evaluation of data, consensus-building, and educational initiatives to shape international standards in bladder cancer care. Key offerings include the IBCG Risk Stratification Framework for clinical decision support, annual retreats for expert collaboration, newsletters for community updates, and trainee membership with travel awards for emerging researchers.

Differentiator

Problem solved

Functional benefit

Products and services

• IBCG Risk Stratification Framework A clinical decision-support framework for stratifying intermediate-risk non-muscle-invasive bladder cancer (NMIBC) patients, adopted by NCCN in 2026 for guiding treatment decisions. Targeted at urologists, oncologists, and clinical researchers managing bladder cancer patients.
• IBCG Annual Retreat An annual in-person working meeting held in Houston where global urological thought leaders collaborate to develop consensus statements, best practices, and high-impact research initiatives that shape bladder cancer care. Intended for IBCG members, clinicians, researchers, and patient advocates.
• IBCG Trainee Membership Program A membership category for current fellows and early-career faculty with strong interest in bladder cancer, offering participation in select IBCG working groups, mentorship from global leaders, networking opportunities, and eligibility for trainee-focused travel awards.
• IBCG Travel Award An annual award supporting outstanding fellows and early-career academic faculty with up to $1,000 in travel support, complimentary hotel accommodation, and full participation in the IBCG Annual Retreat.
• IBCG Newsletters Periodic newsletters (Vol. 1 and Vol. 2 issued annually) featuring updates, milestones, and insights from the IBCG community, archived from 2022 to present. Targeted at IBCG members and the broader urological community.

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• NCCN (National Comprehensive Cancer Network)coreStrategic or Co-development Partner · 1 January 2026IBCG risk stratification framework for intermediate-risk non-muscle-invasive bladder cancer (NMIBC) was adopted into NCCN 2026 Clinical Practice Guidelines. This milestone reflects more than a decade of collaborative work.
• UroTodaycoreStrategic or Co-development PartnerCollaboration through global partnerships to drive progress in bladder cancer research and treatment through shared purpose and strategic alliances.
• BCAN (Bladder Cancer Advocacy Network)coreStrategic or Co-development PartnerActive involvement of patient advocacy network in retreats and initiatives, ensuring patient voices are integrated into therapeutic trials, guidelines, and patient-facing resources.
• WBCPC (World Bladder Cancer Patient Coalition)coreStrategic or Co-development PartnerGlobal coalition bringing patient voices and experiences to shape strategies improving care and outcomes for people affected by bladder cancer worldwide.
• GSRGTminorStrategic or Co-development PartnerCollaboration on rare tumors through joint workshops and educational initiatives.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• International Society of Urological Pathology (ISUP): International expert body establishing consensus standards for urologic pathology. ISUP is comparable to IBCG as an international specialty consortium developing consensus standards across the urologic field.
• Society of Urologic Oncology (SUO): U.S.-based specialty society for urologic oncology clinicians and researchers focused on genitourinary cancers. SUO and IBCG both convene urologic oncology experts to advance research and clinical practice in bladder cancer.
• National Comprehensive Cancer Network (NCCN): U.S.-based alliance of leading cancer centers that issues widely adopted clinical practice guidelines in oncology. NCCN and IBCG both develop and disseminate cancer treatment guidelines, with IBCG's risk stratification framework now incorporated into NCCN's bladder cancer guidelines.

Others

• UroToday: Global provider of urologic oncology news, education, and resources to clinicians. UroToday is a strategic partner of IBCG and comparable as a content distribution and education channel for bladder cancer expertise.

Broad incumbents

• American Society of Clinical Oncology (ASCO): Largest professional oncology society globally, producing clinical guidelines across all cancer types. ASCO and IBCG both operate as expert consensus bodies setting oncologic standards, though ASCO covers a much broader scope.
• American Urological Association (AUA): Largest professional urology association in the U.S., publishing urology guidelines and education across all subspecialties including bladder cancer. AUA covers the broader urology field while IBCG is narrowly focused on bladder cancer.

Emerging players

• World Bladder Cancer Patient Coalition (WBCPC): International coalition of bladder cancer patient organizations. WBCPC collaborates with IBCG on integrating patient voices into guidelines and research, sharing bladder cancer focus across multiple geographies.
• Bladder Cancer Advocacy Network (BCAN): U.S.-based bladder cancer patient advocacy organization. BCAN shares IBCG's exclusive focus on bladder cancer and is a core strategic partner through retreats and patient-centric initiatives.

Regional players

• Canadian Urological Association (CUA): Canadian national urology association producing urology guidelines and educational programs. CUA operates as a regional counterpart to IBCG's international consortium, with overlapping bladder cancer guideline activity.
• European Association of Urology (EAU): European urological association producing clinical guidelines for urologic conditions including bladder cancer. EAU is a regional counterpart publishing parallel guidelines to IBCG's international consortium model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/ibcg_bladderca
• YouTubeyoutube.com/@IBCGMembers

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Bladder Cancer Group